BCG MATRIX‚ GE FOR A PRODUCT PORTFOLIO ERUKULLA SURESH -138919 SCHOOL OF MANAGEMENT‚ NIT WARANGAL SUBJECT: MARKETING ENVIRONMENT AND ANALYSIS ASSIGNMENT-2 SUBMITTED TO DR.RITANJALI MAJHI‚ ASSISTANT PROFESSOR‚ SOM ON 9TH OCTOBER 2013 ABSTRACT BCG matrix is a framework created by Boston Consulting Group to evaluate the strategic position of the business brand portfolio and its potential. It classifies business portfolio into four categories based on industry attractiveness (growth
Premium Strategic management Investment Dimension
BCG Matrix of KFC The need for strategy‚ in order to expand its existing product in very promising markets for KFC is very essential. KFC‚ along with McDonalds‚ and other major fast food chains have dominated the American continent as well as else where. Since the1950’s when the founder of KFC had a dream‚ of building an empire in the fast foodmarket‚ the company has undergone lots of changes. The company has changedownership; it has taken over from Pepsi and passed over to Tricon‚ which owns
Premium Strategic management
including Bayer AG and Novartis are exploring a deal for Merck & Co Inc’s consumer healthcare business‚ as they seek to gain scale in a fragmented industry‚ according to several people familiar with the matter. Reckitt Benckiser Group PLC and Procter & Gamble Co are also among the parties that have held discussions with Merck about buying the unit‚ best known for Coppertone sunscreen and Claritin allergy medicine‚ the sources said this week. The Merck business‚ which also includes Dr. Scholl’s foot
Premium Pharmacology Marketing Pharmacy
| Merck & Company Inc. | Case 1 | | | Introduction of the Company Merck was established in 1891 to improve human and animal health through the development of innovative products. Merck currently has two reportable segments‚ the Pharmaceutical Segment and the Vaccines and Infectious Diseases Segment. Merck sells products through several channels including wholesalers‚ retailers‚ hospitals‚ clinics‚ government and managed health services providers. In the 1980’s the Merck was very
Premium Generic drug Pharmaceutical industry Mergers and acquisitions
Limitations of the BCG model. The BCG model is criticised for having a number of limitations (Kotler 2003; McDonald 2003): ➢ There are other reasons other than relative market share and market growth that could influence the allocation of resources to a product or SBU: reasons such as the need for strong brand name and product positioning could compel resource allocation to an SBU or product (Drummond & Ensor 2004). ➢ What is more‚ the model rests on net cash consumption or generation as the
Premium Marketing Economics Cash flow
Merck Ethics Study In developing a drug to combat river blindness‚ pharmaceutical company Merck discovered an opportunity to treat millions of affected peoples around the world that probably would never see commercial use. The drug in development‚ ivermectin‚ was unaffordable to the primary victims of river blindness‚ Third World peoples. Thus‚ Dr. Vagelos‚ the head of research at the time‚ treaded upon a ethical quagmire; he could either choose to scrap the drug and its further research or
Premium Ethics Philosophy of life Person
heart attacks f) Merck blamed naproxen for skewing the results against Vioxx 3) New England Journal of Medicine Omission g) Merck omits three heart attacks from article submission h) Inclusion of omitted data caused a significantly greater result 4) FDA Reaction i) Letter regarding downplay of risks j) Addition of warning label to Vioxx k) Additional study results 5) Approve Study l) Results with placebo group cause Merck to recall drug
Premium Coronary artery disease Aspirin Hypertension
1. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs? Merck had a 14% increase in sales between 1997 and 1998 and 22% increase in sales from 1998 – 1999‚ and a 13% annual increase in earnings over the same period. Merck’s business strategy consists of two parts: (1) developing and marketing new drugs through internal research‚ and (2) developing partnerships with smaller biotechnology companies. Since 1995‚ Merck had launched
Premium Expected value License Money
Analysis on Merck: Conflict and change Assessment: Merck is one of the biggest pharmaceutical companies in the world today. Although encountered with success‚ it still faces many problems today while trying to be the market leader competing against its competition. While being research and development driven company‚ Merck now has to go beyond R&D to stay competitive in the pharmaceutical industry. The main issue that seems to come
Premium Pharmaceutical industry Pharmacology
TO: Dr. Roy Vagelos‚ Chairman and CEO Merck Corporation. January‚ 1991. The decision to move forward with the program to donate the new drug Mectizan on a large scale to the affected population in the Third World needs to be systematically analyzed. There are two especially important angles from which this decision needs to be considered. The first concern that needs to be taken into account is that of the stockholders and investors in this company‚ whose interests you are ultimately charged with
Premium Medicine Pharmacology Pharmacy